Integra LifeSciences vs Teleflex
IART and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IART and TFX compare
Teleflex is the larger company, worth 5.9 times as much as Integra LifeSciences ($6.6B against $1.1B).
On earnings, Teleflex is cheaper: it trades at 18.8× trailing earnings, against 84.7× for Integra LifeSciences.
Teleflex grew revenue faster over the last twelve months (20.9% versus 0.84% for Integra LifeSciences).
Teleflex keeps more of each dollar of sales as profit, with a net margin of 13.5% compared with 0.79% at Integra LifeSciences.
Teleflex pays a dividend yielding 0.88%; Integra LifeSciences does not pay one.
Teleflex scores higher on the StockData Score (17 against 9 for Integra LifeSciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IART | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $6.6B |
| Share price | $14.40 | $155.10 |
| Change, 1 year | 19.1% | 39.1% |
| Change, 5 years | −79.1% | −51.4% |
| Beta (5Y) | 1.25 | 0.82 |
| Employees | 3,700 | 16K |
| StockData Score | ||
| Total score | 9 | 17 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 2 | 2 |
| Performance score | 3 | 3 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 84.7× | 18.8× (better) |
| P/S | 0.7× (better) | 2.9× |
| P/B | 1.1× (better) | 1.9× |
| EV/EBITDA | 11.1× (better) | 18.4× |
| P/FCF | 13.1× (better) | 27.0× |
| FCF yield | 7.7% (better) | 3.7% |
| Fair value | $14.86 | $215.29 |
| Margin of safety | 3.1% | 28.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.84% | 20.9% (better) |
| Revenue growth, 5Y average | 3.6% (better) | −4.7% |
| Profitability | ||
| Gross margin | 52.4% | 58.3% (better) |
| Operating margin | 4.4% | 9.4% (better) |
| Net margin | 0.79% | 13.5% (better) |
| FCF margin | 5.2% | 10.8% (better) |
| Return on equity | 1.2% | 8.3% (better) |
| Return on invested capital | 5.6% (better) | 3.1% |
| Financial health | ||
| Debt / equity | – | 0.46 |
| Net debt / EBITDA | – | 2.82 |
| Interest coverage | 0.8× | 2.1× (better) |
| Current ratio | 3.62 (better) | 2.01 |
| Altman Z-score | 1.29 | 2.02 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.88% |
| Payout ratio | – | 19.3% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 8.4% |
| Shareholder yield | 0.00% | 9.3% (better) |
| Ownership | ||
| Held by institutions | 94.4% | 113% |
| Held by insiders | 3.4% | 0.73% |
| Insider net buying, 12 months | $0 | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.5% | 9.7% |
Go deeper
- IART stock overview
- IART income statement
- IART valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.